| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/716830/2013 (22.11.13) |
| Publication Date | 22/11/2013 |
| Content Type | News |
|
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in November 2013, recommended adding the treatment of patients with metastatic pancreatic cancer to the approved indications for Abraxane. The CHMP has recommended the approval of Abraxane in combination with gemcitabine, another cancer medicine which is currently the standard therapy in the first-line treatment of adults with metastatic pancreatic cancer. This recommendation offers an additional treatment option for patients who suffer from a type of cancer for which no medicine has been approved since 2007. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001974.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
